Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.

Z. Wang, S. Kar, B. I. Carr

Research output: Contribution to journalArticlepeer-review

Abstract

Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.

Original languageEnglish
Pages (from-to)863-871
Number of pages9
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume8
Issue number8
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.'. Together they form a unique fingerprint.

Cite this